Biotech | August 02, 2021
Takeda and Frazier Healthcare Partners collaborates for Norovirus vaccine candidate
Takeda Will Focus its Efforts on Dengue, Zika and Pandemic vaccines
Takeda Will Focus its Efforts on Dengue, Zika and Pandemic vaccines
The vaccine was 85 percent effective in preventing severe disease across all regions.
Bharat Biotech expects to share further details of the trial results as additional data become available.
The phase 3 clinical trial of Sputnik V will be conducted on 1,500 subjects as part of the randomized, double blind, parallel group placebo controlled study in India.
The Phase 2 study of Sputnik V was conducted on 100 subjects as part of the randomized, double-blind, parallel-group, placebo-controlled study in India.
Subscribe To Our Newsletter & Stay Updated
